Perakizumab (INN) is a humanized monoclonal antibody designed for the treatment of arthritis. It binds to IL17A and acts as an immunomodulator. This drug...
2 KB (67 words) - 01:10, 27 October 2023
(A, B, C, D, E (interleukin 25), F) Antibodies: Brodalumab Ixekizumab Perakizumab Remtolumab Secukinumab Vunakizumab IL-18 Agonists: Iboctadekin Interleukin...
22 KB (1,789 words) - 04:29, 16 July 2024
Bimekizumab Clazakizumab Gevokizumab Ixekizumab Mirikizumab†Lebrikizumab Olokizumab†Perakizumab Risankizumab Spesolimab Tildrakizumab Veterinary Lokivetmab...
38 KB (4,316 words) - 10:24, 26 August 2024
(A, B, C, D, E (interleukin 25), F) Antibodies: Brodalumab Ixekizumab Perakizumab Remtolumab Secukinumab Vunakizumab IL-18 Agonists: Iboctadekin Interleukin...
34 KB (2,690 words) - 02:57, 26 September 2024
Use Authorization (EUA) COVID-19 Pemtumomab Theragyn mouse MUC1 cancer Perakizumab mab humanized IL-17A arthritis Pertuzumab Perjeta mab humanized HER2/neu...
136 KB (4,020 words) - 06:13, 27 September 2024
(A, B, C, D, E (interleukin 25), F) Antibodies: Brodalumab Ixekizumab Perakizumab Remtolumab Secukinumab Vunakizumab IL-18 Agonists: Iboctadekin Interleukin...
17 KB (1,245 words) - 14:04, 2 September 2024
(A, B, C, D, E (interleukin 25), F) Antibodies: Brodalumab Ixekizumab Perakizumab Remtolumab Secukinumab Vunakizumab IL-18 Agonists: Iboctadekin Interleukin...
24 KB (2,070 words) - 07:13, 15 March 2024
(A, B, C, D, E (interleukin 25), F) Antibodies: Brodalumab Ixekizumab Perakizumab Remtolumab Secukinumab Vunakizumab IL-18 Agonists: Iboctadekin Interleukin...
22 KB (2,581 words) - 20:03, 21 June 2024
(A, B, C, D, E (interleukin 25), F) Antibodies: Brodalumab Ixekizumab Perakizumab Remtolumab Secukinumab Vunakizumab IL-18 Agonists: Iboctadekin Interleukin...
16 KB (1,451 words) - 18:24, 2 August 2024
(A, B, C, D, E (interleukin 25), F) Antibodies: Brodalumab Ixekizumab Perakizumab Remtolumab Secukinumab Vunakizumab IL-18 Agonists: Iboctadekin Interleukin...
43 KB (3,661 words) - 19:54, 27 August 2024
(A, B, C, D, E (interleukin 25), F) Antibodies: Brodalumab Ixekizumab Perakizumab Remtolumab Secukinumab Vunakizumab IL-18 Agonists: Iboctadekin Interleukin...
12 KB (1,289 words) - 19:20, 4 December 2023
(A, B, C, D, E (interleukin 25), F) Antibodies: Brodalumab Ixekizumab Perakizumab Remtolumab Secukinumab Vunakizumab IL-18 Agonists: Iboctadekin Interleukin...
14 KB (1,037 words) - 22:20, 19 September 2024
(A, B, C, D, E (interleukin 25), F) Antibodies: Brodalumab Ixekizumab Perakizumab Remtolumab Secukinumab Vunakizumab IL-18 Agonists: Iboctadekin Interleukin...
63 KB (7,473 words) - 11:32, 1 September 2024
(A, B, C, D, E (interleukin 25), F) Antibodies: Brodalumab Ixekizumab Perakizumab Remtolumab Secukinumab Vunakizumab IL-18 Agonists: Iboctadekin Interleukin...
14 KB (1,578 words) - 14:00, 26 February 2024
(A, B, C, D, E (interleukin 25), F) Antibodies: Brodalumab Ixekizumab Perakizumab Remtolumab Secukinumab Vunakizumab IL-18 Agonists: Iboctadekin Interleukin...
12 KB (877 words) - 03:57, 17 September 2024
(A, B, C, D, E (interleukin 25), F) Antibodies: Brodalumab Ixekizumab Perakizumab Remtolumab Secukinumab Vunakizumab IL-18 Agonists: Iboctadekin Interleukin...
5 KB (286 words) - 05:02, 7 September 2024
(A, B, C, D, E (interleukin 25), F) Antibodies: Brodalumab Ixekizumab Perakizumab Remtolumab Secukinumab Vunakizumab IL-18 Agonists: Iboctadekin Interleukin...
14 KB (1,147 words) - 07:33, 11 August 2024
(A, B, C, D, E (interleukin 25), F) Antibodies: Brodalumab Ixekizumab Perakizumab Remtolumab Secukinumab Vunakizumab IL-18 Agonists: Iboctadekin Interleukin...
12 KB (1,323 words) - 14:55, 7 September 2024
(A, B, C, D, E (interleukin 25), F) Antibodies: Brodalumab Ixekizumab Perakizumab Remtolumab Secukinumab Vunakizumab IL-18 Agonists: Iboctadekin Interleukin...
43 KB (5,000 words) - 12:13, 15 September 2024
(A, B, C, D, E (interleukin 25), F) Antibodies: Brodalumab Ixekizumab Perakizumab Remtolumab Secukinumab Vunakizumab IL-18 Agonists: Iboctadekin Interleukin...
26 KB (3,273 words) - 13:58, 26 August 2024
(A, B, C, D, E (interleukin 25), F) Antibodies: Brodalumab Ixekizumab Perakizumab Remtolumab Secukinumab Vunakizumab IL-18 Agonists: Iboctadekin Interleukin...
20 KB (2,192 words) - 23:02, 27 November 2023
(A, B, C, D, E (interleukin 25), F) Antibodies: Brodalumab Ixekizumab Perakizumab Remtolumab Secukinumab Vunakizumab IL-18 Agonists: Iboctadekin Interleukin...
49 KB (6,005 words) - 16:30, 10 June 2024
(A, B, C, D, E (interleukin 25), F) Antibodies: Brodalumab Ixekizumab Perakizumab Remtolumab Secukinumab Vunakizumab IL-18 Agonists: Iboctadekin Interleukin...
11 KB (1,358 words) - 17:09, 6 September 2023
(A, B, C, D, E (interleukin 25), F) Antibodies: Brodalumab Ixekizumab Perakizumab Remtolumab Secukinumab Vunakizumab IL-18 Agonists: Iboctadekin Interleukin...
45 KB (4,194 words) - 12:36, 2 May 2024
(A, B, C, D, E (interleukin 25), F) Antibodies: Brodalumab Ixekizumab Perakizumab Remtolumab Secukinumab Vunakizumab IL-18 Agonists: Iboctadekin Interleukin...
22 KB (2,510 words) - 04:11, 12 August 2024
(A, B, C, D, E (interleukin 25), F) Antibodies: Brodalumab Ixekizumab Perakizumab Remtolumab Secukinumab Vunakizumab IL-18 Agonists: Iboctadekin Interleukin...
19 KB (2,293 words) - 11:05, 8 March 2024
(A, B, C, D, E (interleukin 25), F) Antibodies: Brodalumab Ixekizumab Perakizumab Remtolumab Secukinumab Vunakizumab IL-18 Agonists: Iboctadekin Interleukin...
22 KB (2,786 words) - 02:02, 19 August 2024
(A, B, C, D, E (interleukin 25), F) Antibodies: Brodalumab Ixekizumab Perakizumab Remtolumab Secukinumab Vunakizumab IL-18 Agonists: Iboctadekin Interleukin...
40 KB (4,619 words) - 05:18, 22 August 2024
(A, B, C, D, E (interleukin 25), F) Antibodies: Brodalumab Ixekizumab Perakizumab Remtolumab Secukinumab Vunakizumab IL-18 Agonists: Iboctadekin Interleukin...
9 KB (587 words) - 20:04, 20 December 2023
(A, B, C, D, E (interleukin 25), F) Antibodies: Brodalumab Ixekizumab Perakizumab Remtolumab Secukinumab Vunakizumab IL-18 Agonists: Iboctadekin Interleukin...
35 KB (3,989 words) - 13:32, 13 July 2024